CHA₂DS₂-VASc Score — AFib Stroke Risk
Biological Sex
Female sex adds 1 point but alone does not indicate anticoagulation
Risk Factors — check all that apply
Детальний посібник незабаром
Ми працюємо над детальним навчальним посібником для CHA₂DS₂-VASc Score. Поверніться найближчим часом, щоб переглянути покрокові пояснення, формули, приклади з реального життя та поради експертів.
The CHA₂DS₂-VASc score is a validated clinical risk-stratification tool used worldwide to estimate the annual stroke risk in patients with non-valvular atrial fibrillation (AFib). Atrial fibrillation affects over 33 million people globally and is one of the leading causes of ischaemic stroke — patients with AFib have a 5-fold higher stroke risk than those in normal sinus rhythm, and AFib-related strokes tend to be more severe and more likely to be fatal or disabling. Developed by Lip, Nieuwlaat, Pisters, Lane and Crijns and published in the journal Chest in 2010, CHA₂DS₂-VASc replaced the older CHADS₂ score because it better identifies truly low-risk patients who do not need anticoagulation, while also identifying intermediate-risk patients who benefit from it. The acronym stands for Congestive heart failure, Hypertension, Age ≥ 75 (doubled weight), Diabetes mellitus, Stroke/TIA/thromboembolism history (doubled weight), Vascular disease, Age 65–74, and Sex category (female). Scores range from 0 to 9. A score of 0 in a male (or 1 in a female, where female sex alone is the only risk factor) indicates low risk and anticoagulation is generally not recommended. A score of 1 in a male warrants clinical consideration of anticoagulation. A score of ≥ 2 in a male (or ≥ 3 in a female) strongly supports oral anticoagulation therapy. Current guidelines from the ESC (European Society of Cardiology), AHA/ACC, and CCS incorporate CHA₂DS₂-VASc as the primary stroke-risk assessment tool in AFib management.
CHA₂DS₂-VASc Score = C + H + A₂ + D + S₂ + V + A + Sc Where each letter contributes points as follows: • C — Congestive heart failure or LVEF < 40% → 1 point • H — Hypertension (BP > 140/90 or on antihypertensive medication) → 1 point • A₂ — Age ≥ 75 years → 2 points • D — Diabetes mellitus (fasting glucose > 7 mmol/L or on treatment) → 1 point • S₂ — Prior Stroke, TIA, or systemic thromboembolism → 2 points • V — Vascular disease (prior MI, peripheral artery disease, or aortic plaque) → 1 point • A — Age 65–74 years → 1 point • Sc — Sex category female → 1 point Minimum score: 0 | Maximum score: 9 Note: Age ≥ 75 and Stroke/TIA each carry 2 points because they are the strongest independent predictors of stroke in AFib patients.
- 1Confirm the patient has non-valvular atrial fibrillation (paroxysmal, persistent, or permanent). The score is not validated for valvular AFib (e.g., mitral stenosis or mechanical heart valves), which carries a uniformly high stroke risk requiring anticoagulation regardless of score.
- 2Assess each of the 8 clinical criteria. For age, note that a patient aged 65–74 scores 1 point, while a patient aged ≥ 75 scores 2 points — these are mutually exclusive, so only the higher applicable score is assigned.
- 3Add up all points to obtain the total CHA₂DS₂-VASc score (0–9). Female sex alone (score = 1) does not independently increase stroke risk and guidelines recommend not initiating anticoagulation based solely on female sex.
- 4Interpret the score against the annual stroke risk table: score 0 ≈ 0% risk, score 1 ≈ 1.3%, score 2 ≈ 2.2%, score 3 ≈ 3.2%, score 4 ≈ 4.0%, score 5 ≈ 6.7%, score 6 ≈ 9.8%, score 7 ≈ 9.6%, score 8 ≈ 12.5%, score 9 ≈ 15.2% per year.
- 5Balance stroke risk against bleeding risk using a complementary tool such as the HAS-BLED score before initiating anticoagulation. A high HAS-BLED score is not a contraindication to anticoagulation but identifies modifiable bleeding risk factors to address.
- 6Select the appropriate anticoagulation strategy: NOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin in eligible non-valvular AFib patients based on superior safety and efficacy profiles in landmark trials (RE-LY, ROCKET-AF, ARISTOTLE).
- 7Reassess the CHA₂DS₂-VASc score at least annually and whenever a new clinical event occurs (e.g., new MI, new diagnosis of diabetes, or patient turns 65 or 75), as the risk category can change over time.
Anticoagulation not recommended
This patient has no risk factors whatsoever. The 2020 ESC guidelines recommend against anticoagulation at score 0 in males. Rhythm control and heart rate management remain appropriate goals.
Oral anticoagulation recommended
A score of 2 carries a meaningful annual stroke risk of approximately 2.2%. Both ESC and AHA/ACC guidelines recommend offering oral anticoagulation. A NOAC would be the preferred choice over warfarin.
Anticoagulation strongly indicated
Prior stroke/TIA is the single strongest predictor in the model, contributing 2 points. Combined with age ≥ 75 (another 2 points) and metabolic risk factors, this patient faces nearly a 1-in-10 annual stroke risk without anticoagulation. Immediate initiation of a NOAC (with renal dose adjustment assessment) is strongly recommended.
Do not anticoagulate based on female sex alone
ESC 2020 guidelines explicitly state that female sex should not be used as a sole risk factor to initiate anticoagulation. A score of 1 driven solely by female sex is equivalent to a male score of 0. This patient should be reassessed annually as new risk factors develop.
Guiding initiation of oral anticoagulation (NOAC or warfarin) in newly diagnosed AFib to prevent ischaemic stroke and systemic embolism, enabling practitioners to make well-informed quantitative decisions based on validated computational methods and industry-standard approaches
Annual reassessment of AFib patients to determine whether anticoagulation should be started, continued, or reconsidered as risk factors evolve, helping analysts produce accurate results that support strategic planning, resource allocation, and performance benchmarking across organizations
Shared decision-making discussions between clinicians and patients about the balance of stroke prevention benefits versus bleeding risks of long-term anticoagulation, allowing professionals to quantify outcomes systematically and compare scenarios using reliable mathematical frameworks and established formulas
Emergency department evaluation of patients presenting with palpitations or incidentally detected AFib to prioritise stroke-prevention planning, supporting data-driven evaluation processes where numerical precision is essential for compliance, reporting, and optimization objectives
Population health stratification in cardiology registries and quality-improvement programmes to identify undertreated high-risk AFib patients, which requires precise quantitative analysis to support evidence-based decisions, strategic resource allocation, and performance optimization across diverse organizational contexts and professional disciplines
Female sex as sole risk factor
A CHA₂DS₂-VASc score of 1 due entirely to female sex should not trigger anticoagulation. ESC 2020 guidelines explicitly state that female sex is a 'risk modifier' rather than an independent risk factor, and anticoagulation is not recommended unless at least one additional clinical risk factor is present. This distinction prevents unnecessary anticoagulation in low-risk women.
Valvular atrial fibrillation
The score is not applicable to patients with moderate-to-severe rheumatic mitral stenosis or mechanical prosthetic heart valves. These patients have high stroke risk by definition and require anticoagulation with warfarin regardless of CHA₂DS₂-VASc score. NOACs are contraindicated in patients with mechanical heart valves (RE-ALIGN trial showed harm with dabigatran).
AFib detected incidentally or subclinically
Device-detected subclinical atrial fibrillation (SCAF) and short runs of atrial high-rate episodes (AHRE) detected by pacemakers or loop recorders represent an evolving area. Current evidence does not uniformly support applying CHA₂DS₂-VASc thresholds designed for clinical AFib to SCAF — ongoing trials (ARTESIA, NOAH-AFNET 6) are informing guidelines for this population.
Chronic kidney disease
CKD is not a CHA₂DS₂-VASc criterion but significantly impacts NOAC dosing and choice. All NOACs require renal function assessment (CrCl by Cockcroft-Gault) at initiation and monitoring every 6–12 months. Dabigatran is contraindicated if CrCl < 30 mL/min. Apixaban has the most favourable renal profile. Dialysis patients require specialist guidance as NOACs are generally avoided.
Hypertrophic cardiomyopathy with AFib
Patients with hypertrophic cardiomyopathy (HCM) and AFib have very high stroke risk independent of CHA₂DS₂-VASc score. Current HCM guidelines recommend oral anticoagulation for all HCM patients with AFib regardless of CHA₂DS₂-VASc score, as HCM itself represents a high-risk substrate not captured by the scoring system.
| Score | Annual Stroke Risk | Recommendation | NNT to prevent 1 stroke/yr |
|---|---|---|---|
| 0 (male) | ~0% | No anticoagulation | — |
| 1 (female only) | ~0% | No anticoagulation | — |
| 1 (male) | ~1.3% | Consider anticoagulation | ~77 |
| 2 | ~2.2% | Anticoagulate | ~45 |
| 3 | ~3.2% | Anticoagulate | ~31 |
| 4 | ~4.0% | Anticoagulate | ~25 |
| 5 | ~6.7% | Anticoagulate | ~15 |
| 6 | ~9.8% | Anticoagulate | ~10 |
| 7 | ~9.6% | Anticoagulate | ~10 |
| 8 | ~12.5% | Anticoagulate | ~8 |
| 9 | ~15.2% | Anticoagulate | ~7 |
What is the CHA₂DS₂-VASc score used for?
The CHA₂DS₂-VASc score estimates the annual risk of ischaemic stroke or systemic thromboembolism in patients with non-valvular atrial fibrillation. It guides clinicians in deciding whether to initiate oral anticoagulation therapy (such as warfarin or a NOAC) to prevent stroke. It is the most widely recommended stroke-risk tool in international cardiology guidelines including those from the ESC, AHA/ACC, and CCS.
What score requires anticoagulation?
In males, a score of ≥ 2 is generally considered an indication to offer oral anticoagulation, and a score of 1 warrants clinical consideration. In females, the threshold is ≥ 3 (because female sex alone adds 1 point without independently increasing stroke risk). A score of 0 in males or 1 in females (female sex only) indicates low risk where anticoagulation is not recommended.
Why does the score go to 9 and not 10?
The maximum score is 9, not 10, because the age criteria are mutually exclusive — a patient aged ≥ 75 scores 2 points (A₂), which replaces the 1-point score for age 65–74 (A). Since you cannot score both simultaneously, the theoretical maximum is 9 (all factors present with age ≥ 75): CHF(1) + HTN(1) + Age≥75(2) + DM(1) + Stroke(2) + Vascular(1) + Female(1) = 9.
What is the difference between CHA₂DS₂-VASc and the older CHADS₂ score?
The original CHADS₂ score (2001) used 5 factors: CHF, Hypertension, Age ≥ 75, Diabetes (each 1 point), and prior Stroke/TIA (2 points), with a maximum of 6. CHA₂DS₂-VASc added vascular disease, age 65–74, and female sex as additional risk factors, improving discrimination particularly for low-risk patients. Studies show CHA₂DS₂-VASc better identifies truly low-risk patients who do not need anticoagulation and better classifies intermediate-risk patients who benefit from it.
Does a high CHA₂DS₂-VASc score mean anticoagulation is safe?
Not necessarily. The CHA₂DS₂-VASc score only estimates stroke risk — it does not assess bleeding risk. The HAS-BLED score should be calculated alongside CHA₂DS₂-VASc to identify and correct modifiable bleeding risk factors (e.g., uncontrolled hypertension, alcohol excess, concomitant antiplatelet use). A high HAS-BLED score is not a contraindication to anticoagulation but signals the need for closer monitoring and risk-factor modification.
Can CHA₂DS₂-VASc be used for valvular atrial fibrillation?
No. CHA₂DS₂-VASc is validated only for non-valvular atrial fibrillation. Patients with AFib associated with moderate-to-severe mitral stenosis or mechanical heart valves have uniformly high stroke risk and require anticoagulation regardless of their CHA₂DS₂-VASc score. Warfarin (not NOACs) is the recommended anticoagulant for patients with mechanical valves. Understanding this aspect of cha2ds2 vasc is important for obtaining accurate and meaningful results in both clinical and analytical contexts.
Which anticoagulants are preferred based on a high score?
For eligible patients with non-valvular AFib and a CHA₂DS₂-VASc score indicating anticoagulation, NOACs (direct oral anticoagulants) — apixaban, rivaroxaban, dabigatran, and edoxaban — are preferred over vitamin K antagonists like warfarin in most guidelines. NOACs have demonstrated equivalent or superior efficacy and a better bleeding safety profile in major randomised trials. Renal function must be assessed before prescribing, particularly for dabigatran.
How often should the CHA₂DS₂-VASc score be recalculated?
Clinicians should reassess the score at least annually and immediately after any qualifying clinical event — such as a new myocardial infarction, new peripheral artery disease diagnosis, new stroke or TIA, new diagnosis of diabetes or heart failure, or when a patient crosses an age threshold (turns 65 or 75). Risk category can change over time, potentially moving a patient from a 'no anticoagulation' recommendation into the 'anticoagulate' category.
Порада профі
Always assess the CHA₂DS₂-VASc score together with the HAS-BLED bleeding risk score. A high HAS-BLED score should prompt correction of modifiable bleeding risk factors (e.g., uncontrolled hypertension, alcohol excess, concomitant antiplatelet or NSAID use) — not avoidance of anticoagulation. The net clinical benefit of anticoagulation is positive at CHA₂DS₂-VASc ≥ 2 for males (≥ 3 for females) even in the presence of elevated bleeding risk.
Чи знаєте ви?
The CHA₂DS₂-VASc score has been validated in over 100 independent studies across multiple continents and is now embedded in clinical decision-support systems in hospitals worldwide. Interestingly, a large Danish registry study (Olesen et al., BMJ 2011) found that the annual stroke rate in patients with a score of 0 was just 0.78% — essentially the same as the background population rate — confirming that these patients derive little net benefit from anticoagulation and can safely be managed without it.
Джерела
- ›Lip GY et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach — Chest 2010
- ›ESC 2020 Guidelines for Atrial Fibrillation — European Heart Journal
- ›January CT et al. 2019 AHA/ACC/HRS Focused Update of 2014 AF Guidelines — JACC 2019
- ›Olesen JB et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in atrial fibrillation — BMJ 2011
- ›Camm AJ et al. 2012 focused update of ESC Guidelines for management of atrial fibrillation — European Heart Journal 2012